Literature DB >> 20229125

Exercise and zoledronic acid on lipid profile and bone remodeling in ovariectomized rats: a paradoxical negative association?

E Lespessailles1, C Jaffré, G Y Rochefort, E Dolléans, C L Benhamou, D Courteix.   

Abstract

Exercise (EXE) and amino-bisphosphonates (BP) are both considered as useful strategies in the prevention of post-menopausal bone loss. Exercise reduces lipid levels, and BP may induce increase in high-density lipoprotein cholesterol (HDL-C). We hypothesized that combined effects of BP and exercise would produce a better improvement of lipid profile. We studied the specific and combined effects of zoledronic acid (Z) and EXE on lipid profile and bone remodeling in mature ovariectomized (OVX) rats. Six-month old female rats were randomly assigned to either a sham-ovx group (n = 12) or one of four OVX groups (n = 12): vehicle-treated sedentary (OVX); OVX + EXE (OVX-E, running on a treadmill for 12 weeks); OVX + Z (20 microg/kg, i.v.), (OVX-Z); OVX + Z+EXE (OVX-ZE). Total cholesterol (TC), HDL-C and bone remodeling markers were measured at baseline and at the end of the study. We demonstrated that both Z and EXE prevented the increase in bone resorption resulting from OVX, and individually improved the atherosclerotic risk index. Therapy with Z resulted in significant increase (39.00 +/- 0.03 vs. 53.6 +/- 0.01 mg/dl; +37.4%, P < 0.05) in serum concentration of HDL-C and a non significant decrease in TC (135.30 +/- 0.03 vs. 144.80 +/- 0.05 mg/dl; -5.8%) in the OVX-Z group compared to the OVX group. Post-menopausal women have elevated risk of CVD and bone resorption, hence, these data ultimately demonstrate (except for the elevated ratio in the combined group) that exercise and zoledronic acid are useful in minimizing the impact of these two processes in women and the combination of the two may be clinically relevant.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20229125     DOI: 10.1007/s11745-010-3399-y

Source DB:  PubMed          Journal:  Lipids        ISSN: 0024-4201            Impact factor:   1.880


  34 in total

1.  Protein geranylgeranylation is required for osteoclast formation, function, and survival: inhibition by bisphosphonates and GGTI-298.

Authors:  F P Coxon; M H Helfrich; R Van't Hof; S Sebti; S H Ralston; A Hamilton; M J Rogers
Journal:  J Bone Miner Res       Date:  2000-08       Impact factor: 6.741

Review 2.  The anti-inflammatory effect of exercise: its role in diabetes and cardiovascular disease control.

Authors:  Bente Klarlund Pedersen
Journal:  Essays Biochem       Date:  2006       Impact factor: 8.000

3.  New developments in lipid-lowering therapy: the role of inhibitors of hydroxymethylglutaryl-coenzyme A reductase.

Authors:  J A Tobert
Journal:  Circulation       Date:  1987-09       Impact factor: 29.690

4.  Changes in serum HDL and LDL cholesterol in patients with Paget's bone disease treated with pamidronate.

Authors:  A Montagnani; S Gonnelli; C Cepollaro; M S Campagna; M B Franci; S Pacini; C Gennari
Journal:  Bone       Date:  2003-01       Impact factor: 4.398

5.  Chronic intravenous aminobisphosphonate therapy increases high-density lipoprotein cholesterol and decreases low-density lipoprotein cholesterol.

Authors:  S Adami; V Braga; G Guidi; D Gatti; D Gerardi; E Fracassi
Journal:  J Bone Miner Res       Date:  2000-03       Impact factor: 6.741

6.  Time-dependent changes in biochemical bone markers and serum cholesterol in ovariectomized rats: effects of raloxifene HCl, tamoxifen, estrogen, and alendronate.

Authors:  C A Frolik; H U Bryant; E C Black; D E Magee; S Chandrasekhar
Journal:  Bone       Date:  1996-06       Impact factor: 4.398

7.  Effect of body weight on osteopenia in ovariectomized rats.

Authors:  T J Wronski; P A Schenck; M Cintrón; C C Walsh
Journal:  Calcif Tissue Int       Date:  1987-03       Impact factor: 4.333

8.  Time course of osteoblast appearance after in vivo mechanical loading.

Authors:  M D Boppart; D B Kimmel; J A Yee; D M Cullen
Journal:  Bone       Date:  1998-11       Impact factor: 4.398

9.  The estradiol-stimulated lipoprotein receptor of rat liver. A binding site that membrane mediates the uptake of rat lipoproteins containing apoproteins B and E.

Authors:  E E Windler; P T Kovanen; Y S Chao; M S Brown; R J Havel; J L Goldstein
Journal:  J Biol Chem       Date:  1980-11-10       Impact factor: 5.157

10.  The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis.

Authors:  Dennis M Black; Susan L Greenspan; Kristine E Ensrud; Lisa Palermo; Joan A McGowan; Thomas F Lang; Patrick Garnero; Mary L Bouxsein; John P Bilezikian; Clifford J Rosen
Journal:  N Engl J Med       Date:  2003-09-20       Impact factor: 91.245

View more
  1 in total

1.  Endurance training enhances LXRα gene expression in Wistar male rats.

Authors:  Fatemeh Kazeminasab; Mohammad Marandi; Kamran Ghaedi; Fahimeh Esfarjani; Jamal Moshtaghian
Journal:  Eur J Appl Physiol       Date:  2013-05-15       Impact factor: 3.078

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.